Should a patient receiving a GLP‑1 receptor agonist injection who develops depressive symptoms or suicidal ideation discontinue the medication, and what alternative glucose‑lowering therapies are recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

GLP-1 Receptor Agonists and Depression/Suicidality: Clinical Management

Do not routinely discontinue GLP-1 receptor agonists in patients who develop depressive symptoms or suicidal ideation, as the evidence shows these medications are not associated with increased suicidality during active treatment and may actually reduce suicide risk compared to some alternatives.

Evidence Summary and Risk Profile

During Active Treatment

The psychiatric safety profile during GLP-1 RA use is reassuring:

  • No increased suicide risk: A nationwide cohort study found GLP-1 RAs were not associated with increased suicide or suicide attempts compared to SGLT2 inhibitors (HR 0.93,95% CI 0.57-1.52), and showed lower risk compared to DPP-4 inhibitors (HR 0.58,95% CI 0.37-0.91) 1

  • Reduced suicidality versus sulfonylureas: GLP-1 RAs demonstrated lower risk for suicidal ideation compared to sulfonylureas (HR 0.62,95% CI 0.44-0.87) 2

  • Safe in treated depression: Among patients with type 2 diabetes and pre-existing treated depression, GLP-1 RA initiation showed no higher suicidality risk versus SGLT2 inhibitors (HR 0.88,95% CI 0.74-1.05) and was associated with lower all-cause mortality (HR 0.64,95% CI 0.58-0.71) 3

Depression and Anxiety Findings

The data on depression and anxiety are more nuanced:

  • Compared to SGLT2 inhibitors, GLP-1 RAs showed modestly higher risks of depression (HR 1.19-1.20) and anxiety (HR 1.09) 4, 2
  • Compared to DPP-4 inhibitors, results were neutral or showed minimal differences 4, 2
  • Critical distinction: These associations reflect depression/anxiety diagnoses, not suicidality or self-harm

Post-Discontinuation Risk

This is where vigilance is required: After GLP-1 RA cessation, there is an increased risk of depressive and anxiety disorders compared to prior use of DPP-4 inhibitors or SGLT2 inhibitors 5. This increase is modestly mediated by elevated triglyceride levels after stopping the medication.

Clinical Algorithm

If Depression/Suicidal Ideation Develops During GLP-1 RA Treatment:

  1. Assess severity and acuity:

    • Active suicidal ideation with plan/intent → immediate psychiatric evaluation (standard crisis management)
    • Mild-moderate depressive symptoms without suicidality → continue GLP-1 RA

  2. Initiate or optimize psychiatric treatment:

    • Start/adjust antidepressant therapy
    • Arrange psychiatric follow-up
    • Continue the GLP-1 RA given neutral-to-favorable safety profile

  3. Consider medication context:

    • If patient was recently on sulfonylureas, the switch to GLP-1 RA may actually improve psychiatric outcomes 2
    • Pre-existing treated depression is not a contraindication 3

Alternative Glucose-Lowering Therapies (If Discontinuation Required):

Per ADA 2025 guidelines, if GLP-1 RA must be discontinued for any reason 6:

  • SGLT2 inhibitors: Preferred alternative given cardiorenal benefits and comparable psychiatric safety profile
  • DPP-4 inhibitors: Acceptable alternative with neutral psychiatric profile
  • Avoid sulfonylureas: Higher suicidality risk compared to GLP-1 RAs 2
  • Basal insulin: Consider if A1C >10% or glucose ≥300 mg/dL 6

Post-Discontinuation Monitoring:

If GLP-1 RA is discontinued, implement heightened psychiatric surveillance for 6-12 months given the increased risk of anxiety and depression after cessation 5:

  • Monitor for emerging depressive/anxiety symptoms
  • Check triglyceride levels (mechanism for post-cessation risk)
  • Consider prophylactic psychiatric referral for high-risk patients

Critical Pitfalls to Avoid

  • Do not reflexively discontinue GLP-1 RAs when psychiatric symptoms emerge—the medication itself is not causative and may be protective
  • Do not confuse depression/anxiety risk with suicidality risk—these are distinct outcomes with different risk profiles
  • Do not overlook post-cessation risk—the period after stopping GLP-1 RAs requires more vigilance than during active treatment 5
  • Do not avoid GLP-1 RAs in patients with treated depression—evidence supports safety in this population 3

Guideline Context

The 2025 ADA guidelines recommend GLP-1 RAs as preferred agents for overweight/obese patients with type 2 diabetes and for those with cardiovascular disease 6, 7. The psychiatric safety data support continuing this recommendation, as the cardiovascular and metabolic benefits substantially outweigh the modest and inconsistent psychiatric signals observed in some comparisons.

References

Related Questions

Do glucagon-like peptide‑1 (GLP‑1) receptor agonists cause depression?
In an adult patient who has been using Adderall (amphetamine/dextroamphetamine) 10 mg sporadically and is now establishing care, can I initiate a daily dose of 10 mg?
How do the cardiac valves open and close during the cardiac cycle?
In a patient with heart failure and a pulmonary capillary wedge pressure of 24 mmHg, cardiac output of 4 L/min, and cardiac index of 1.8 L/min/m², should milrinone or dobutamine be used?
What is the recommended starting dose of Adderall XR (mixed amphetamine salts) for an adult with ADHD?
Can flavoxate tablets be used to control pain associated with a urinary tract infection?
Does mouth breathing with an open mouth prevent bruxism (teeth grinding)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.